Abstracts tagged "risk and thrombosis"

Abstract Number: 379 • ACR/ARHP Annual Meeting 2018
Risk Factors of Venous Thromboembolism in Idiopathic Inflammatory Myopathies
Julien Campagne¹, Thomas Moulinet², Jonathan Epstein³, Sabine Revuz⁴, Francois Maurier⁵, Marie-Hélène Schuhmacher⁶, Philippe Evon⁷, Alain Meyer⁸ and Roland Jaussaud², ¹Médecine Interne, Centre Hospitalier Régional Universitaire de Nancy, Vandoeuvre-lès-Nancy, France, ²Médecine Interne, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France, ³Inserm, CIC-1433 Epidémiologie Clinique, Vandoeuvre-lès-Nancy, France, ⁴Médecine Interne, Hôpitaux Privés de Metz, Metz, France, ⁵Médecine interne, Hôpitaux Privés de Metz, Metz, France, ⁶Médecine Interne, Centre Hospitalier Emile Durkheim, Epinal, France, ⁷Médecine Interne, Centre Hospitalier Jeanne d'Arc, Bar-le-Duc, France, ⁸Médecine Interne, Centre Hospitalier Régional Universitaire de Strasbourg, Strasbourg, France
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are heterogeneous disorders characterised by skeletal muscle weakness and muscle inflammation. IIM includes dermatomyositis (DM), polymyositis (PM), antisynthetase syndromes (ASS),…
Abstract Number: 2760 • ACR/ARHP Annual Meeting 2017
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION) Clinical Database and Repository (“Registry”) Analysis: First and Recurrent Thrombosis Risk after 1201 Patient-Years of Follow-up
Ozan Unlu¹, Danieli Andrade², Alessandra Banzato³, D. Ware Branch⁴, Paul R. Fortin⁵, Maria Gerosa⁶, Roger A. Levy⁷, Michelle Lopes⁸, Michelle Petri⁹, Ignasi Rodriguez¹⁰, Maria Tektonidou¹¹, Amaia Ugarte¹², Rohan Willis¹³, Doruk Erkan¹⁴ and , on Behalf of APS ACTION .¹⁵, ¹Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., Sao Paulo, Brazil, ³Department of Cardiac Thoracic and Vascular Sciences, Clinical Cardiology, Thrombosis Centre, University of Padova, Padova, Italy, ⁴Obstetrics and Gynecology, University of Utah and Intermountain Healthcare, Salt Lake City, UT, ⁵Medicine, CHU de Quebec - Universite de Laval, Quebec, QC, Canada, ⁶Istituto Ortopedico Gaetano Pini, University of Milan, Milano, Italy, ⁷Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁸Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁹Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ¹⁰Rheumatology, Hospital Clinica, Barcelona, Spain, ¹¹First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, ¹²Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Biscay, Spain, ¹³Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ¹⁴Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ¹⁵., New York, NY
Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic…
Abstract Number: 1799 • ACR/ARHP Annual Meeting 2016
Smoking, Antiphospholipid Antibodies and Thrombosis in SLE
Michelle Petri¹, George Stojan² and Wei Fu³, ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, MD
Background/Purpose: Anticardiolipin Ever smoking 411 (48.1%) Past smoking 246 (49.8%) Current smoking 165 (46.6%) Never smoking 721 (48.9%) P Value (Ever vs. Never) 0.6943…
Abstract Number: 1965 • ACR/ARHP Annual Meeting 2016
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: First and Recurrent Thrombosis Risk after 720 Patient-Years of Follow-up
Ozan Unlu¹, W. David Branch², Paul R. Fortin³, Maria Gerosa⁴, Guillermo J. Pons-Estel⁵, Maria Tektonidou⁶, Amaia Ugarte⁷, Doruk Erkan⁸ and On Behalf of APS ACTION .⁹, ¹Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Obstetrics and Gynecology, University of Utah and Intermountain Healthcare, Salt Lake City, UT, ³Medicine, CHU de Québec - Université Laval, Québec, QC, Canada, ⁴University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁵Department of Autoimmune Diseases, Institut Clínic de Medicina i Dermatologia, Hospital Clínic de Barcelona, Barcelona, Spain, ⁶First Department of Internal Medicine, School of Medicine, National University of Athens, Athens, Greece, ⁷Hospital Universitario Cruces, Biscay, Spain, ⁸Rheumatology, Hospital for Special Surgery- Weill Cornell Medicine, New York, NY, ⁹., New York, NY
Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients. Previously, based on…